Heart failure with preserved ejection fraction (HFpEF) has emerged as a particularly challenging clinical and public health disorder [1] . An extraordinary research commitment over the past four decades has been rewarded by the development of effective drug, surgical, antiarrhythmic, and device therapy for patients suffering from heart failure with reduced ejection fraction (HFrEF). The most recent development has been the pivotal randomized clinical trial (RCT) showing the mortality and morbidity benefits of catheter ablation in HFrEF [2] .
In contrast, the search of good therapeutic options for HFpEF has been difficult. There is no Btriple^drug regimen as in HFrEF. Diuretics can relieve congestion, and some angiotensin receptor antagonists may reduce hospitalization for heart failure but neither has been shown to prolong survival [3] . Nitrates remain controversial, with trials challenging even symptom relief [4] . Spironolactone may have benefits in subpopulations [5, 6] . Atrial fibrillation (AF) in HFpEF can be the clinical trigger for cardiovascular collapse, as many clinicians can testify from their own individual experiences, and is substantiated by culled data from population studies such as the Framingham study and AF clinical trials [7, 8] . The prevalence of AF in HFpEF is high, with both being diseases of the elderly and hypertension is a frequent comorbidity that promotes both conditions. Obesity may also have a role in promoting HFpEF and AF. The mechanical basis for HFpEF has been a subject of debate and few definitive atrial or ventricular function parameters have been identified as being pathognomonic with HFpEF. Most recently, attention has focused on global longitudinal strain, left atrial volume, right ventricular volumes and mitral valvular regurgitation in this entity [9, 10] . Left atrial dysfunction is intimately linked to left ventricular systolic and diastolic dysfunction. In fact, variation in therapeutic effect may exist with different strata of left ventricular ejection fraction in HFpEF [10] .
Antiarrhythmic interventions for AF associated with HFpEF are scarce. Antiarrhythmic drugs have been used in this setting but clinical trial data are sparse. Some recent reanalyses of the AFFIRM trial have shown that the rhythm control strategy delayed the development of progressive heart failure compared to a rate control approach [11, 12] . More recent analyses suggest that even a modest amount of documented sinus rhythm was associated with this benefit [13] . Dronedarone employed in the ATHENA trial was used in a subpopulation with impaired and preserved left ventricular function and a history of prior heart failure [14] . In a post hoc analysis, 693 patients were identified who had a NYHA class I/II/III heart failure of whom 184 had HFrEF. The remainder had HFpEF and but their outcomes were not reported separately from those without HF. Catheter ablation has been applied in HFrEF in observational studies and now in an RCT [2] . However, no significant published data is currently available in AF with HFpEF.
Interestingly, pacing studies have emerged for this condition. Multisite atrial pacing has been shown to have beneficial hemodynamic and rhythm control effects in this condition. In an early report in brady-tachy population without clear identification of HFpEF, dual site atrial pacing combined with antiarrhythmic drugs and/or limited ablation showed favorable left atrial and ventricular hemodynamic effects as well as rhythm control efficacy [15, 16] . Early acute studies with biatrial dual site pacing have shown acute hemodynamic benefits for left atrial and cardiac performance [17, 18] . However, the electrophysiologic community focused largely on the beneficial effects of electrical atrial resynchronization and had limited attention span for its hemodynamic benefits. While the role of atrial performance in HFpEF has long been considered, few have examined the value of multisite atrial pacing interventions. There has been no extrapolation of the obvious potential clinical benefit to the AF-HFpEF population. In one clinical series, Eicher et al. described an atrial Bdyssynchronyŝ yndrome in patients with interatrial conduction delay, atrial fibrillation and symptomatic HFpEF [19] . They noted the dramatic decongestive effects of biatrial pacing in patients with NYHA class III and IV heart failure symptoms, harkening back to similar reports in HFrEF and ventricular dyssynchrony. Nagarakanti and coworkers reported significant atrial reverse remodeling and preservation of left ventricular systolic function with long-term dual site right atrial pacing [20] . Of importance is the suggestion that both restoration of rhythm control and beneficial effects on left atrial-left ventricular transport could be synergistic in this scenario. The latter mechanism may be a unique benefit of atrial resynchronization approaches in AF with HFpEF. Our group has recently described survival and rhythm control with longterm dual site right atrial pacing in a hybrid therapy prescription in AF with HFpEF [21] . While this observational data is consistent with significant improvements in outcomes, including severity of heart failure and all-cause mortality, these findings would require prospective trials for validation.
It is increasingly apparent that electrophysiologic interventions could have potential benefit in the clinically challenging and unsolved dilemma of managing patients with AF associated with HFpEF. The role of rhythm control and its electrophysiologic benefits and resynchronization therapy with attendant hemodynamic benefits needs to be explored. The added value of pacing techniques in resynchronization therapy for hemodynamic advantage is similarly ripe for exploration in HFpEF, akin to ventricular-paced resynchronization in HFrEF. These pilot studies could engender real value clinical trials in this unsolved enormous and, as yet, unsolved public health challenge.
